Anixa Biosciences moves CAR-T ovarian cancer trial to highest dose yet
Anixa Biosciences has treated a second patient at the top dose in its Phase 1 CAR-T trial for recurrent ovarian cancer. The move puts new pressure on its risky valuation and tests the faith of company insiders.